NYSE:NVS

Fondation Botnar and Novartis Support EDCTP Fellowships on Child and Adolescent Health

Press Release

May 6, 2020 /3BL Media/ - Fondation Botnar and Novartis will support research capacity development in sub-Saharan Africa within the framework of EDCTP’s 2020 Career Development Fellowships. Collectively, the two organisations will contribute up to a maximum of €2.25 million to the initial EDCTP call budget of €1.5 million. Their investments will support successful proposals to conduct research on child and adolescent health with a focus on the interaction between poverty-related infectious diseases and non-communicable diseases.

Novartis US Foundation Supports Telehealth Programs to Provide Access to Care for New Jersey’s Most Vulnerable Communities

Summary: 
  • Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
  • The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic  
  • Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care
Press Release
  • Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state
  • The Grant enabled NJ community health centers to quickly implement telehealth to maintain continuity of care for underserved communities, especially critical during the current COVID-19 pandemic  
  • Novartis US Foundation supports programs to reimagine healthcare through use of digital tools to reduce barriers to care

Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients

Summary: 
  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
     
  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
  • Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
  • Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines
Press Release
  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease
     
  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if medicine is approved for COVID-19
  • Study complements Novartis commitment to donate up to 130 million doses of hydroxychloroquine globally to support the COVID-19 pandemic response
  • Novartis has a broad COVID-19 research and development commitment, including multiple large sponsored and investigator initiated clinical trials of its medicines

Celebrating the First World Chagas Disease Day

Press Release

For the first time in history, the global health community is preparing to celebrate World Chagas Disease Day. Novartis is joining the global movement to raise visibility and awareness of patients with Chagas disease1.

Novartis and the Novartis US Foundation Establish USD 5 Million US COVID-19 Community Response Fund

Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak
Summary: 
  • Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak
  • First grants to focus on immediate need for digital tools and frontline medical organization needs:
    • USD 250,000 grant to the Commons Project for development of COVIDcheck, a free public digital health service under development with global, national, state and local public health authorities
    • USD 125,000 grants to each Americares and Direct Relief to support US safety net clinics
  • US COVID-19 Community Response Fund builds on other Novartis global initiatives to respond to the pandemic, including a USD 20 million Global Response Fund, commitment to donate up to 130 million doses of hydroxychloroquine globally, and participation in industry-wide R&D collaboration with, among others, the Bill & Melinda Gates Foundation
Press Release
  • Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak
  • First grants to focus on immediate need for digital tools and frontline medical organization needs:
    • USD 250,000 grant to the Commons Project for development of COVIDcheck, a free public digital health service under development with global, national, state and local public health authorities
    • USD 125,000 grants to each Americares and Direct Relief to support US safety net clinics
  • US COVID-19 Community Response Fund builds on other Novartis global initiatives to respond to the pandemic, including a USD 20 million Global Response Fund, commitment to donate up to 130 million doses of hydroxychloroquine globally, and participation in industry-wide R&D collaboration with, among others, the Bill & Melinda Gates Foundation

Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic Alongside Bill & Melinda Gates Foundation

Collaboration to address product development and scale up challenges posed by current pandemic
Press Release

BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide.

Novartis Commits to Donate up to 130 Million Doses of Hydroxychloroquine to Support the Global COVID-19 Pandemic Response

Summary: 
  • Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19
  • Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
  • Commitment builds on recently announced USD 20 million Novartis COVID19 Response Fund, drug discovery and development collaborations and essential medicines price stability
  • Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients 
Press Release
  • Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19
  • Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
  • Commitment builds on recently announced USD 20 million Novartis COVID19 Response Fund, drug discovery and development collaborations and essential medicines price stability
  • Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients 

International Research Partnership and EDCTP to Invest €44m in Next-generation Antimalarials to Combat Drug-resistant Malaria in Africa

Summary: 
  • EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
     
  • The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
     
  • The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
Press Release
  • EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
     
  • The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
     
  • The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.

Novartis and DNDi to Collaborate on the Development of a New Oral Drug to Treat Visceral Leishmaniasis

Media Update • Media Update • Media Update
Summary: 

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

  • LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
  • Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
  • DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
  • Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year
Press Release

Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

  • LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
  • Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
  • DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
  • Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year

Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People

Healthcare companies and philanthropies to fund training of thousands of community health workers as part of larger initiative led by Last Mile Health and Living Goods to advance universal health coverage
Press Release

BASEL, SWITZERLAND/NEW YORK, 16 January 2020 /3BL Media/ –  Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation have joined forces with Last Mile Health and Living Goods to increase access to community-based primary healthcare for nearly 1.7 million people in up to six African countries, as part of their shared commitment to accelerate universal health coverage. The Health Worker Training Initiative is a three-year investment, generously matched by The Audacious Project, and totals USD $18 million.

Pages

Subscribe to NYSE:NVS